+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Hurthle Cell Carcinoma Treatment Market by Therapy Type, Drug Class, Route Of Administration, End User, Distribution Channel - Global Forecast 2025-2030- Product Image
Hurthle Cell Carcinoma Treatment Market by Therapy Type, Drug Class, Route Of Administration, End User, Distribution Channel - Global Forecast 2025-2030- Product Image
Sale

Hurthle Cell Carcinoma Treatment Market by Therapy Type, Drug Class, Route Of Administration, End User, Distribution Channel - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 193 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 5674555
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Hurthle Cell Carcinoma Treatment Market is undergoing notable transformation, driven by advances in targeted therapies, immuno-oncology, and evolving supply chain strategies. Stakeholders across the pharmaceutical and healthcare sectors are increasingly focused on developing differentiated, patient-centric solutions in the context of this challenging thyroid malignancy.

Market Snapshot: Hurthle Cell Carcinoma Treatment Market

The Hurthle Cell Carcinoma Treatment Market grew from USD 6.82 billion in 2024 to USD 7.27 billion in 2025. It is expected to continue growing at a CAGR of 6.52%, reaching USD 9.96 billion by 2030. Expansion is supported by continuous investment in precision medicine, expanded access to diagnostic technologies, and the integration of new treatment modalities. Market activity remains dynamic as leading players adopt innovative solutions to address recurring and resistant disease, while infrastructure investment and reimbursement policies shape the pace of adoption across key regions.

Scope & Segmentation

This report covers comprehensive segmentation and trend analysis to inform strategic investment and operational planning:

  • Therapy Type: Chemotherapy, Immunotherapy (including CTLA-4 Inhibitors and PD-1 Inhibitors), Radioactive Iodine Therapy, Targeted Therapy, and Thyroidectomy
  • Drug Class: Conventional Chemotherapeutics, Monoclonal Antibodies, Radiopharmaceuticals, Small Molecule Inhibitors (including Multi-Kinase and Tyrosine Kinase Inhibitors)
  • Route of Administration: Intravenous and Oral
  • End User: Ambulatory Surgery Center, Cancer Institute, Hospital, Specialty Clinic
  • Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
  • Region: Americas (United States, Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (United Kingdom, Germany, France, and additional markets), Asia-Pacific (China, India, Japan, and others)
  • Key Companies: Eisai Co., Ltd., Bayer AG, Novartis AG, Ipsen S.A., Pfizer Inc., Exelixis, Inc., Merck & Co., Inc., Bristol-Myers Squibb Company, AstraZeneca PLC, Roche Holding AG

Key Takeaways for Decision-Makers

  • Immunotherapy and targeted treatments are rapidly shaping therapeutic standards, particularly for disease unresponsive to traditional interventions.
  • Adoption of advanced molecular diagnostics enables more personalized therapies and informs biomarker-driven clinical decision-making.
  • Collaborative models, including partnerships between large pharma, agile biotechs, and academic institutions, are accelerating innovation pipelines.
  • Region-specific access and reimbursement policies remain central to clinical uptake, underscoring the need for localized market entry and patient support strategies.
  • Digital health platforms and telemedicine are emerging as solutions for improved patient monitoring, adherence, and post-intervention outcomes.
  • Supply chain and procurement flexibility, with an emphasis on nearshoring and diversification, is critical to maintaining product availability amid global uncertainties.

Tariff Impact: Navigating US Tariff Revisions in 2025

The 2025 revision of import tariffs in the United States directly impacts the cost structures for biologics, specialized reagents, and radiopharmaceuticals in the Hurthle Cell Carcinoma Treatment Market. Pharmaceutical firms and research organizations are responding with robust supply chain strategies—such as nearshoring, supplier diversification, and enhanced logistics protocols—to safeguard continuity of raw material sourcing and mitigate inflationary risks. These adaptations are further driving collaboration across procurement, regulatory, and reimbursement functions to ensure uninterrupted patient access and competitive positioning.

Methodology & Data Sources

This report employs a multi-tiered methodology, including secondary literature review, structured expert interviews, and robust data triangulation. Primary insights were obtained from relevant clinical, regulatory, and supply chain experts, complemented by peer-reviewed studies and global clinical trial registries. Cross-referencing and scenario modeling were used for validation, ensuring findings are dependable and actionable for decision-making.

Why This Report Matters

  • Provides clarity on market-defining trends and strategic levers, equipping executives to drive innovation and respond to evolving therapeutic demands.
  • Delivers actionable segmentation analysis tailored for commercial teams, enabling precise targeting and resource allocation across therapies, drug classes, and regions.
  • Equips stakeholders with risk mitigation insights relevant to shifting regulatory, supply chain, and policy landscapes.

Conclusion

The Hurthle Cell Carcinoma Treatment Market is defined by innovation, operational adaptation, and patient-focused care. Stakeholders prepared to leverage strategic partnerships and invest in emerging technologies will navigate this evolving landscape with resilience and opportunity.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Accelerated FDA review of novel tyrosine kinase inhibitors for Hurthle cell carcinoma broadens therapeutic options
5.2. Integration of next-generation sequencing biomarker panels to personalize Hurthle cell carcinoma treatment strategies
5.3. Emerging clinical data for PD-1 and PD-L1 inhibitors in refractory Hurthle cell carcinoma patient populations
5.4. Advancements in circulating tumor DNA assays enabling minimally invasive monitoring of Hurthle cell carcinoma progression
5.5. Adoption of combination therapy regimens evaluating immunotherapy with targeted agents in advanced Hurthle cell carcinoma
5.6. Increased payer coverage negotiations driven by real-world evidence on cost effectiveness of novel Hurthle cell carcinoma treatments
5.7. Implementation of AI-driven imaging analytics to improve detection and staging accuracy in Hurthle cell carcinoma diagnosis
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Hurthle Cell Carcinoma Treatment Market, by Therapy Type
8.1. Introduction
8.2. Chemotherapy
8.3. Immunotherapy
8.3.1. CTLA-4 Inhibitors
8.3.2. PD-1 Inhibitors
8.4. Radioactive Iodine Therapy
8.5. Targeted Therapy
8.6. Thyroidectomy
9. Hurthle Cell Carcinoma Treatment Market, by Drug Class
9.1. Introduction
9.2. Conventional Chemotherapeutics
9.3. Monoclonal Antibodies
9.4. Radiopharmaceuticals
9.5. Small Molecule Inhibitors
9.5.1. Multi-Kinase Inhibitors
9.5.2. Tyrosine Kinase Inhibitors
10. Hurthle Cell Carcinoma Treatment Market, by Route Of Administration
10.1. Introduction
10.2. Intravenous
10.3. Oral
11. Hurthle Cell Carcinoma Treatment Market, by End User
11.1. Introduction
11.2. Ambulatory Surgery Center
11.3. Cancer Institute
11.4. Hospital
11.5. Specialty Clinic
12. Hurthle Cell Carcinoma Treatment Market, by Distribution Channel
12.1. Introduction
12.2. Hospital Pharmacy
12.3. Online Pharmacy
12.4. Retail Pharmacy
13. Americas Hurthle Cell Carcinoma Treatment Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Hurthle Cell Carcinoma Treatment Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Hurthle Cell Carcinoma Treatment Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Eisai Co., Ltd.
16.3.2. Bayer AG
16.3.3. Novartis AG
16.3.4. Ipsen S.A.
16.3.5. Pfizer Inc.
16.3.6. Exelixis, Inc.
16.3.7. Merck & Co., Inc.
16.3.8. Bristol-Myers Squibb Company
16.3.9. AstraZeneca PLC
16.3.10. Roche Holding AG
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. HURTHLE CELL CARCINOMA TREATMENT MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY THERAPY TYPE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY THERAPY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 8. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 14. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. HURTHLE CELL CARCINOMA TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. HURTHLE CELL CARCINOMA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 25. HURTHLE CELL CARCINOMA TREATMENT MARKET: RESEARCHAI
FIGURE 26. HURTHLE CELL CARCINOMA TREATMENT MARKET: RESEARCHSTATISTICS
FIGURE 27. HURTHLE CELL CARCINOMA TREATMENT MARKET: RESEARCHCONTACTS
FIGURE 28. HURTHLE CELL CARCINOMA TREATMENT MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. HURTHLE CELL CARCINOMA TREATMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY CTLA-4 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY CTLA-4 INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY PD-1 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY PD-1 INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY RADIOACTIVE IODINE THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY RADIOACTIVE IODINE THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY THYROIDECTOMY, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY THYROIDECTOMY, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY CONVENTIONAL CHEMOTHERAPEUTICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY CONVENTIONAL CHEMOTHERAPEUTICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY RADIOPHARMACEUTICALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY RADIOPHARMACEUTICALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY MULTI-KINASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY MULTI-KINASE INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY AMBULATORY SURGERY CENTER, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY AMBULATORY SURGERY CENTER, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY CANCER INSTITUTE, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY CANCER INSTITUTE, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY HOSPITAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY SPECIALTY CLINIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY SPECIALTY CLINIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. AMERICAS HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 68. AMERICAS HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 69. AMERICAS HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 70. AMERICAS HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 71. AMERICAS HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 72. AMERICAS HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 73. AMERICAS HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 74. AMERICAS HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 75. AMERICAS HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 76. AMERICAS HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 77. AMERICAS HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 78. AMERICAS HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 79. AMERICAS HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 80. AMERICAS HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 81. AMERICAS HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 82. AMERICAS HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 83. UNITED STATES HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 84. UNITED STATES HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 85. UNITED STATES HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 86. UNITED STATES HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 87. UNITED STATES HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 88. UNITED STATES HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 89. UNITED STATES HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 90. UNITED STATES HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 91. UNITED STATES HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 92. UNITED STATES HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 93. UNITED STATES HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 94. UNITED STATES HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 95. UNITED STATES HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 96. UNITED STATES HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 97. UNITED STATES HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 98. UNITED STATES HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 99. CANADA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 100. CANADA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 101. CANADA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 102. CANADA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 103. CANADA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 104. CANADA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 105. CANADA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 106. CANADA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 107. CANADA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 108. CANADA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 109. CANADA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 110. CANADA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 111. CANADA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 112. CANADA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 113. MEXICO HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 114. MEXICO HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 115. MEXICO HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 116. MEXICO HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 117. MEXICO HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 118. MEXICO HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 119. MEXICO HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 120. MEXICO HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 121. MEXICO HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 122. MEXICO HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 123. MEXICO HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 124. MEXICO HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 125. MEXICO HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 126. MEXICO HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 127. BRAZIL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 128. BRAZIL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 129. BRAZIL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 130. BRAZIL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 131. BRAZIL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 132. BRAZIL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 133. BRAZIL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 134. BRAZIL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 135. BRAZIL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 136. BRAZIL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 137. BRAZIL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 138. BRAZIL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 139. BRAZIL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 140. BRAZIL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 141. ARGENTINA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 142. ARGENTINA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 143. ARGENTINA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 144. ARGENTINA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 145. ARGENTINA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 146. ARGENTINA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 147. ARGENTINA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 148. ARGENTINA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 149. ARGENTINA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 150. ARGENTINA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 151. ARGENTINA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 152. ARGENTINA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 153. ARGENTINA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 154. ARGENTINA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 155. EUROPE, MIDDLE EAST & AFRICA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 156. EUROPE, MIDDLE EAST & AFRICA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 157. EUROPE, MIDDLE EAST & AFRICA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 158. EUROPE, MIDDLE EAST & AFRICA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 159. EUROPE, MIDDLE EAST & AFRICA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 160. EUROPE, MIDDLE EAST & AFRICA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 161. EUROPE, MIDDLE EAST & AFRICA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 162. EUROPE, MIDDLE EAST & AFRICA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 163. EUROPE, MIDDLE EAST & AFRICA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 164. EUROPE, MIDDLE EAST & AFRICA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 165. EUROPE, MIDDLE EAST & AFRICA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 166. EUROPE, MIDDLE EAST & AFRICA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 167. EUROPE, MIDDLE EAST & AFRICA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 168. EUROPE, MIDDLE EAST & AFRICA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 169. EUROPE, MIDDLE EAST & AFRICA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 170. EUROPE, MIDDLE EAST & AFRICA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 171. UNITED KINGDOM HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 172. UNITED KINGDOM HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 173. UNITED KINGDOM HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 174. UNITED KINGDOM HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 175. UNITED KINGDOM HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 176. UNITED KINGDOM HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 177. UNITED KINGDOM HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 178. UNITED KINGDOM HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 179. UNITED KINGDOM HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 180. UNITED KINGDOM HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 181. UNITED KINGDOM HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 182. UNITED KINGDOM HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 183. UNITED KINGDOM HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 184. UNITED KINGDOM HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 185. GERMANY HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 186. GERMANY HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 187. GERMANY HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 188. GERMANY HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 189. GERMANY HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 190. GERMANY HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 191. GERMANY HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 192. GERMANY HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 193. GERMANY HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 194. GERMANY HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 195. GERMANY HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 196. GERMANY HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 197. GERMANY HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 198. GERMANY HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 199. FRANCE HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 200. FRANCE HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 201. FRANCE HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 202. FRANCE HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 203. FRANCE HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 204. FRANCE HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 205. FRANCE HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 206. FRANCE HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 207. FRANCE HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 208. FRANCE HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 209. FRANCE HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 210. FRANCE HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 211. FRANCE HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 212. FRANCE HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 213. RUSSIA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 214. RUSSIA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 215. RUSSIA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 216. RUSSIA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 217. RUSSIA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 218. RUSSIA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 219. RUSSIA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 220. RUSSIA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 221. RUSSIA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 222. RUSSIA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 223. RUSSIA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 224. RUSSIA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 225. RUSSIA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 226. RUSSIA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 227. ITALY HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 228. ITALY HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 229. ITALY HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 230. ITALY HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 231. ITALY HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 232. ITALY HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 233. ITALY HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 234. ITALY HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 235. ITALY HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 236. ITALY HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 237. ITALY HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 238. ITALY HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 239. ITALY HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 240. ITALY HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 241. SPAIN HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 242. SPAIN HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 243. SPAIN HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 244. SPAIN HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 245. SPAIN HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 246. SPAIN HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 247. SPAIN HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 248. SPAIN HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 249. SPAIN HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 250. SPAIN HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 251. SPAIN HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 252. SPAIN HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 253. SPAIN HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 254. SPAIN HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 255. UNITED ARAB EMIRATES HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 256. UNITED ARAB EMIRATES HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 257. UNITED ARAB EMIRATES HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 258. UNITED ARAB EMIRATES HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 259. UNITED ARAB EMIRATES HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 260. UNITED ARAB EMIRATES HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 261. UNITED ARAB EMIRATES HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 262. UNITED ARAB EMIRATES HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 263. UNITED ARAB EMIRATES HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 264. UNITED ARAB EMIRATES HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 265. UNITED ARAB EMIRATES HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 266. UNITED ARAB EMIRATES HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 267. UNITED ARAB EMIRATES HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 268. UNITED ARAB EMIRATES HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 269. SAUDI ARABIA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 270. SAUDI ARABIA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 271. SAUDI ARABIA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 272. SAUDI ARABIA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 273. SAUDI ARABIA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 274. SAUDI ARABIA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 275. SAUDI ARABIA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 276. SAUDI ARABIA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 277. SAUDI ARABIA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 278. SAUDI ARABIA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 279. SAUDI ARABIA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 280. SAUDI ARABIA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 281. SAUDI ARABIA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 282. SAUDI ARABIA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 283. SOUTH AFRICA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 284. SOUTH AFRICA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 285. SOUTH AFRICA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 286. SOUTH AFRICA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 287. SOUTH AFRICA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 288. SOUTH AFRICA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 289. SOUTH AFRICA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 290. SOUTH AFRICA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 291. SOUT

Samples

Loading
LOADING...

Companies Mentioned

  • Eisai Co., Ltd.
  • Bayer AG
  • Novartis AG
  • Ipsen S.A.
  • Pfizer Inc.
  • Exelixis, Inc.
  • Merck & Co., Inc.
  • Bristol-Myers Squibb Company
  • AstraZeneca PLC
  • Roche Holding AG

Table Information

Report AttributeDetails
No. of Pages193
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 7.27 Billion
Forecasted Market Value ( USD ) by 2030 $ 9.96 Billion
Compound Annual Growth Rate6.5%
Regions CoveredGlobal
No. of Companies Mentioned10

Related Topics

Related Reports

Thyroid Cancer Drugs Market by Cancer Type (Anaplastic Thyroid Cancer (ATC), Follicular Thyroid Cancer (FTC), Hürthle Cell Carcinoma), Treatment Modality (Chemotherapy, Immunotherapy, Radioiodine Therapy), Drug Type, Mode Of Administration, End User - Global Forecast 2025-2030 - Product Image

Thyroid Cancer Drugs Market by Cancer Type (Anaplastic Thyroid Cancer (ATC), Follicular Thyroid Cancer (FTC), Hürthle Cell Carcinoma), Treatment Modality (Chemotherapy, Immunotherapy, Radioiodine Therapy), Drug Type, Mode Of Administration, End User - Global Forecast 2025-2030

  • Report
  • 188 Pages
  • Global
From
Nasopharyngeal Carcinoma Treatment Market Report 2025 - Product Image

Nasopharyngeal Carcinoma Treatment Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Adrenocortical Carcinoma Treatment - Global Strategic Business Report - Product Image

Adrenocortical Carcinoma Treatment - Global Strategic Business Report

  • Report
  • 289 Pages
  • Global
From
Adrenocortical Carcinoma Treatment Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type - Product Image

Adrenocortical Carcinoma Treatment Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type

  • Report
  • 79 Pages
  • Global
From
Immune Checkpoint Inhibitors for Cancer Market by Indication (Bladder Cancer, Head and Neck Cancer, Melanoma), Mechanism of Action (Ctla4 Inhibitor, Pd1 Inhibitor, Pdl1 Inhibitor), Treatment Modality, Therapy Line, End User - Global Forecast 2025-2030 - Product Image

Immune Checkpoint Inhibitors for Cancer Market by Indication (Bladder Cancer, Head and Neck Cancer, Melanoma), Mechanism of Action (Ctla4 Inhibitor, Pd1 Inhibitor, Pdl1 Inhibitor), Treatment Modality, Therapy Line, End User - Global Forecast 2025-2030

  • Report
  • 189 Pages
  • Global
From

About the Hurthle Cell Carcinoma Drug Market

The Hurthle Cell Carcinoma Drug market is a subset of the larger Thyroid Cancer Drugs market. Hurthle Cell Carcinoma is a rare form of thyroid cancer, and the drugs used to treat it are typically targeted therapies. These drugs are designed to target specific genetic mutations that are associated with the cancer, and they are often used in combination with other treatments such as surgery and radiation. The drugs used to treat Hurthle Cell Carcinoma are typically expensive, and they are often not covered by insurance. As a result, the market for these drugs is relatively small. The companies in the Hurthle Cell Carcinoma Drug market include AbbVie, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Merck, Novartis, Pfizer, and Roche. These companies are all major players in the pharmaceutical industry, and they are all actively researching and developing new treatments for Hurthle Cell Carcinoma. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.